Edition:
India

Syndax Pharmaceuticals Inc (SNDX.OQ)

SNDX.OQ on NASDAQ Stock Exchange Global Select Market

10.72USD
23 Apr 2018
Change (% chg)

$-0.31 (-2.81%)
Prev Close
$11.03
Open
$11.00
Day's High
$11.02
Day's Low
$10.70
Volume
7,806
Avg. Vol
104,693
52-wk High
$15.35
52-wk Low
$7.43

Chart for

About

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb... (more)

Overall

Beta: --
Market Cap(Mil.): $270.64
Shares Outstanding(Mil.): 22.22
Dividend: --
Yield (%): --

Financials

  SNDX.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -2.99 -- --
ROI: -42.86 14.84 14.38
ROE: -48.61 16.34 16.07

BRIEF-Syndax Pharmaceuticals Reports Q4 Loss Per Share $0.80

* SYNDAX PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE

06 Mar 2018

BRIEF-Syndax Pharmaceuticals Reports Qtrly Loss Per Share $0.80

* SYNDAX PHARMACEUTICALS - PHASE 2 ENCORE 601 PD-(L)1 REFRACTORY MELANOMA COHORT DATA AND MELANOMA REGISTRATION STRATEGY DISCLOSURE FORTHCOMING IN 2Q18

06 Mar 2018

BRIEF-Syndax Announces Immuno-Oncology Clinical Trial Collaboration With Astrazeneca

* SYNDAX ANNOUNCES IMMUNO-ONCOLOGY CLINICAL TRIAL COLLABORATION WITH ASTRAZENECA

01 Feb 2018

BRIEF-Syndax Pharmaceuticals Announces Clinical Collaboration To Evaluate Entinostat In Combination With Anti-Pd-L1 Cancer Immunotherapy In Breast Cancer

* SYNDAX PHARMACEUTICALS ANNOUNCES CLINICAL COLLABORATION TO EVALUATE ENTINOSTAT IN COMBINATION WITH ANTI-PD-L1 CANCER IMMUNOTHERAPY IN BREAST CANCER

10 Jan 2018

BRIEF-Syndax Pharmaceuticals reports Q3 loss per share $0.68

* Syndax pharmaceuticals reports third quarter 2017 financial results and provides clinical and business update

08 Nov 2017

Competitors

  Price Chg
Pfizer Inc. (PFE.N) $36.80 +0.17
Novartis AG (NOVN.S) CHF76.04 -0.04
Eli Lilly And Co (LLY.N) $80.20 +1.14

Earnings vs. Estimates